Full Text Journal Articles by
Author Walter Reinisch

Advertisement

Find full text journal articles






Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease.

Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, William J Sandborn, Marc Ferrante, John K Marshall, Walter Reinisch, Parambir S Dulai,

This study evaluated the minimal clinically important short-term improvement in the MM-SES-CD, a novel modified scoring system of the SES-CD, that reliably predicted one-year ER. This post-hoc analysis of two CD clinical trial programs pooled data of 198 participants with baseline ulcers and SES-CD ≥3 who had baseline, post-induction (8-12 ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients.

Amanda Ricciuto, Christopher A Lamb, Eric I Benchimol, Gareth J Walker, Nicholas A Kennedy, M Ellen Kuenzig, Gilaad G Kaplan, Michael D Kappelman, Ryan C Ungaro, Jean-Frederic Colombel, Erica J Brenner, Manasi Agrawal, Walter Reinisch, Anne M Griffiths, Shaji Sebastian,

<h4>Background and aims</h4>Age is a major prognostic factor for COVID-19 outcomes. The effect of IBD activity on COVID-19 is unclear. We examined the relationship between IBD activity and COVID-19 severity according to age.<h4>Methods</h4>We included IBD patients diagnosed with COVID-19, reported to SECURE-IBD between March 13, 2020-August 3, 2021. Clinical IBD ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

Brian G Feagan, Reena Khanna, William J Sandborn, Séverine Vermeire, Walter Reinisch, Chinyu Su, Leonardo Salese, Haiyun Fan, Jerome Paulissen, Deborah A Woodworth, Wojciech Niezychowski, Bruce E Sands,

<h4>Background</h4>Endoscopy is routine in trials of ulcerative colitis therapies.<h4>Aim</h4>To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.

Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Jean-Frederic Colombel, Walter Reinisch,

<h4>Background and aims</h4>There is paucity of evidence on the reversibility of Crohn's disease [CD]-related strictures treated with therapies. We aimed to describe the clinical and endoscopic outcomes of CD patients with non-passable strictures.<h4>Methods</h4>This was a post-hoc analysis of three large CD clinical trial programmes examining outcomes with infliximab, ustekinumab, and ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(10):1649-1657]

Cited: 0 times

View full text PDF listing >>



Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of Over 6,000 Patients from an International Registry.

Ryan C Ungaro, Erica J Brenner, Manasi Agrawal, Xian Zhang, Michael D Kappelman, Jean-Frederic Colombel, ,

Gastroenterology (Gastroenterology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease.

Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr,

Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates. Model-informed precision dosing (MIPD) with population pharmacokinetic models could help to individualize infliximab dosing regimens and improve therapy. The aim of ... Read more >>

Pharmaceutics (Pharmaceutics)
[2021, 13(9):]

Cited: 0 times

View full text PDF listing >>



Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.

Geert R D'Haens, Walter Reinisch, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Kłopocka, Jochen Klaus, Stefan Schreiber, Dong Il Park, Xavier Hébuterne, Peter Nagy, Fabio Cataldi, Steven W Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth J Gorelick, William J Sandborn,

<h4>Background</h4>Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension study, assessed the long-term safety and efficacy of ontamalimab in patients with moderate-to-severe ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis.

Emily C L Wong, Jean-Frederic Colombel, Robert Riddell, John K Marshall, Walter Reinisch, Parambir S Dulai, Neeraj Narula,

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease.

Christian Primas, Gertrud Hopf, Sieglinde Reinisch, Lukas Baumann, Gottfried Novacek, Walter Reinisch, Harald Vogelsang,

<h4>Background and aims</h4>Fecal calprotectin (fCP) has been shown to correlate with endoscopic disease activity in Crohn's disease (CD). The aim of this study was to evaluate its role in predicting early endoscopic recurrence in postoperative CD.<h4>Methods</h4>Patients who underwent CD-related intestinal resection with ileocolonic anastomosis were prospectively followed up until ileocolonoscopy ... Read more >>

Scand J Gastroenterol (Scandinavian journal of gastroenterology)
[2021, 56(10):1169-1174]

Cited: 0 times

View full text PDF listing >>



New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry.

Ryan C Ungaro, Manasi Agrawal, Erica J Brenner, Xian Zhang, Jean-Frederic Colombel, Michael D Kappelman, Walter Reinisch,

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.

Neeraj Narula, Emily C L Wong, John K Marshall, Jean-Frederic Colombel, Parambir S Dulai, Walter Reinisch,

<h4>Background & aims</h4>Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs vedolizumab for moderate to severe biologic-naïve UC using patient-level data from clinical trial program data sets.<h4>Methods</h4>This was a post hoc analysis of 3 UC clinical trial programs that ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study.

Neeraj Narula, Emily C L Wong, Mahshid Dehghan, Andrew Mente, Sumathy Rangarajan, Fernando Lanas, Patricio Lopez-Jaramillo, Priyanka Rohatgi, P V M Lakshmi, Ravi Prasad Varma, Andres Orlandini, Alvaro Avezum, Andreas Wielgosz, Paul Poirier, Majid A Almadi, Yuksel Altuntas, Kien Keat Ng, Jephat Chifamba, Karen Yeates, Thandi Puoane, Rasha Khatib, Rita Yusuf, Kristina Bengtsson Boström, Katarzyna Zatonska, Romaina Iqbal, Liu Weida, Zhu Yibing, Li Sidong, Antonio Dans, Afzalhussein Yusufali, Noushin Mohammadifard, John K Marshall, Paul Moayyedi, Walter Reinisch, Salim Yusuf,

<h4>Objective</h4>To evaluate the relation between intake of ultra-processed food and risk of inflammatory bowel disease (IBD).<h4>Design</h4>Prospective cohort study.<h4>Setting</h4>21 low, middle, and high income countries across seven geographical regions (Europe and North America, South America, Africa, Middle East, south Asia, South East Asia, and China).<h4>Participants</h4>116 087 adults aged 35-70 years with at ... Read more >>

BMJ (BMJ (Clinical research ed.))
[2021, 374:n1554]

Cited: 0 times

View full text PDF listing >>



Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.

Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, Robert Riddell, John K Marshall, Walter Reinisch, Parambir S Dulai,

<h4>Background & aims</h4>The prognostic value of histologic scores, grades, and individual histologic subcomponents, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histoendoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis remains uncertain.<h4>Methods</h4>We performed a post hoc analysis of participants from the VARSITY trial (n = 734 ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical Decision Support Tool for Infliximab in Crohn's Disease.

Parambir S Dulai, Emily C L Wong, Walter Reinisch, Neeraj Narula,

Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



PEG and mucosal biofilms in irritable bowel syndrome and ulcerative colitis.

Walter Reinisch,

Gastroenterology (Gastroenterology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.

Emily C L Wong, Elisa Buffone, So Jeong Lee, Parambir S Dulai, John K Marshall, Walter Reinisch, Neeraj Narula,

<h4>Background and aims</h4>It is unclear whether early symptom improvement in Crohn's disease [CD] provides any prognostic information for patients long-term. This paper aims to investigate the relationship between early patient-reported outcomes [PROs] after completion of induction of infliximab, and their relationship with long-term clinical remission [CR] and endoscopic remission [ER].<h4>Methods</h4>This ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(7):1114-1119]

Cited: 0 times

View full text PDF listing >>



COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States.

Manasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, Xian Zhang, Gilaad G Kaplan, Siew C Ng, Walter Reinisch, Flavio Steinwurz, James D Lewis, Michele Kissous-Hunt, Irene Modesto, Ryan C Ungaro, Jean-Frederic Colombel, Michael D Kappelman,

The coronavirus disease 2019 (COVID-19) has affected more than 29 million people and led to more than 542,000 deaths in the United States.<sup>1</sup> Older age, comorbidities, and racial and ethnic minority status are associated with severe COVID-19.<sup>2</sup> Among patients with inflammatory bowel disease (IBD), racial and ethnic minorities have worse ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, 19(10):2210-2213.e3]

Cited: 0 times

View full text PDF listing >>



Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.

David T Rubin, Walter Reinisch, Thomas Greuter, Paulo G Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R Vavricka, Gary R Lichtenstein,

<h4>Introduction</h4>Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs, and the impact of tofacitinib on EIMs in patients with UC in the OCTAVE clinical ... Read more >>

Therap Adv Gastroenterol (Therapeutic advances in gastroenterology)
[2021, 14:17562848211005708]

Cited: 0 times

View full text PDF listing >>



Reply.

Emily C L Wong, Parambir S Dulai, Neil K Sengupta, John K Marshall, Jean-Frederic Colombel, Walter Reinisch, Neeraj Narula,

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY

Ryan C. Ungaro, Manasi Agrawal, Erica J. Brenner, Xian Zhang, Jean Frederic Colombel, Michael Kappelman, Walter Reinisch,

Gastroenterology (Gastroenterology)
[2021, 160(6):S-332-S-333]

Cited: 0 times

View full text PDF listing >>



Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS

Gilaad Kaplan, Fox E. Underwood, Divine Tanyingoh, Manasi Agrawal, Ryan C. Ungaro, Erica J. Brenner, Richard Gearry, Michele Kissous-Hunt, James D. Lewis, Siew C. Ng, Jean-Francois Rahier, Walter Reinisch, Flavio Steinwurz, Xian Zhang, Michael Kappelman, Jean Frederic Colombel,

Gastroenterology (Gastroenterology)
[2021, 160(6):S-525-S-525]

Cited: 0 times

View full text PDF listing >>



Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.

Manasi Agrawal, Erica J Brenner, Xian Zhang, Jean-Frederic Colombel, Michael D Kappelman, Ryan C Ungaro, , Richard B Gearry, Gilaad G Kalpan, Michele Kissous-Hunt, James D Lewis, Siew C Ng, Jean-Francois Rahier, Walter Reinisch, Frank M Ruemmele, Flavio Steinwurz, Fox E Underwood,

<h4>Background</h4>We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry.<h4>Methods</h4>IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(5):860-863]

Cited: 3 times

View full text PDF listing >>



The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.

Neeraj Narula, Achuthan Aruljothy, Emily C L Wong, Ravi Homenauth, Abdul-Aziz Alshahrani, John K Marshall, Walter Reinisch,

This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo-treated patients at weeks 6 and 52.<h4>Background and aims</h4>The UNITI trials demonstrated that UST was effective in inducing and maintaining clinical remission in Crohn's disease (CD). ... Read more >>

United European Gastroenterol J (United European gastroenterology journal)
[2021, 9(5):581-589]

Cited: 1 time

View full text PDF listing >>



Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.

Walter Reinisch, William J Sandborn, Silvio Danese, Xavier Hébuterne, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul A Hellstern, Joo Sung Kim, Miles P Sparrow, Kenneth J Gorelick, Michael Hoy, Martina Goetsch, Caleb Bliss, Charu Gupta, Fabio Cataldi, Séverine Vermeire,

<h4>Background and aims</h4>Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II.<h4>Methods</h4>TURANDOT II was a phase 2, multicentre, open-label [OL] study in patients with moderate-to-severe UC ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(6):938-949]

Cited: 2 times

View full text PDF listing >>



Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.

Kevin L Winthrop, Edward V Loftus, Daniel C Baumgart, Walter Reinisch, Chudy I Nduaka, Nervin Lawendy, Gary Chan, Rajiv Mundayat, Gary S Friedman, Leonardo Salese, Andrew J Thorpe, Chinyu Su,

<h4>Background and aims</h4>Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes.<h4>Methods</h4>Three cohorts were analysed: Induction [P2/3 induction studies]; Maintenance [P3 maintenance study]; and Overall [all tofacitinib-treated patients in induction, maintenance, or ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(6):914-929]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

4.4517 s